LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Contents
Segment reporting for single reportable segment
- Segment reporting for single reportable segment
The following table presents the components of net income or loss, which is the measure of profit or loss used for the Company’s single reportable segment:
| Three months endedSeptember 30, | Nine months endedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues | $25,322 | $31,109 | $82,682 | $105,686 |
| Personnel costs(1) | 9,815 | 11,129 | 32,284 | 35,393 |
| Materials and non-depreciation overhead(2) | 9,574 | 14,273 | 31,600 | 41,572 |
| Depreciation | 2,410 | 1,981 | 7,235 | 5,968 |
| Stock-based compensation | 1,715 | 2,392 | 5,498 | 6,404 |
| Reorganization costs | 720 | 1,571 | 3,509 | 5,104 |
| Loss on sale or disposal of assets | — | — | — | 7,738 |
| All other operating expenses(3) | 1,982 | 2,830 | 5,555 | 5,170 |
| Interest expense, net | 7,868 | 6,326 | 22,695 | 17,280 |
| Change in fair value of debt derivative liability | 31,270 | 375 | 35,628 | 1,991 |
| Other expense (income), net | 1 | (110) | (219) | (359) |
| Income tax expense | 51 | 333 | 117 | 359 |
| Net loss | $(40,084) | $(9,991) | $(61,220) | $(20,934) |
(1)Includes all wages and salary, bonus, employer taxes, and employee benefit plan expenses
(2)Represents cost of sales, excluding direct labor and all personnel cost and depreciation allocations
(3)Includes expenses for accounting, legal and other professional services, software licensing, insurance costs, public company costs and board fees.
For the three months ended September 30, 2026, the Company earned revenue of approximately 90% in the United States and 10% in all other countries combined. For the three months ended September 30, 2025, the Company earned revenue of approximately 60% in the United States,20% in Belgium,10% in the Netherlands and 10% in all other countries combined. For the nine months ended September 30, 2026, the Company earned revenue of approximately 80% in the United States,10% in Belgium and 10% in all other countries combined. For the nine months ended September 30, 2025, the Company earned revenue of approximately 60% in the United States,25% in Belgium and 15% in all other countries combined.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.